Hyperinflammation vs Infection: The Diagnostic Grey Zone in the ICU

A Clinical Review for Critical Care Physicians

Dr Neeraj Manikath , claude.ai

Abstract

Background: The differentiation between hyperinflammatory syndromes and infectious processes represents one of the most challenging diagnostic dilemmas in critical care medicine. Macrophage activation syndrome (MAS), hemophagocytic lymphohistiocytosis (HLH), severe sepsis, and cytokine storm share overlapping clinical features, laboratory abnormalities, and pathophysiological mechanisms, creating a diagnostic grey zone that significantly impacts therapeutic decision-making.

Objective: To provide critical care physicians with a comprehensive framework for distinguishing between hyperinflammatory and infectious etiologies in critically ill patients, emphasizing practical diagnostic approaches, therapeutic implications, and clinical pearls.

Methods: This narrative review synthesizes current literature on hyperinflammatory syndromes in the ICU setting, with emphasis on differential diagnosis and practical management strategies.

Conclusions: Early recognition and differentiation of these conditions is crucial for appropriate therapeutic intervention. A systematic approach combining clinical assessment, laboratory parameters, and targeted investigations can improve diagnostic accuracy and patient outcomes.

Keywords: Hyperinflammation, sepsis, macrophage activation syndrome, hemophagocytic lymphohistiocytosis, cytokine storm, critical care

Introduction

The intensive care unit (ICU) frequently presents clinicians with patients exhibiting severe systemic inflammatory responses that challenge our diagnostic acumen. The clinical syndromes of macrophage activation syndrome (MAS), hemophagocytic lymphohistiocytosis (HLH), severe sepsis/septic shock, and cytokine storm represent a spectrum of hyperinflammatory conditions with significant phenotypic overlap¹. This diagnostic uncertainty has profound therapeutic implications, as the management strategies for infectious versus non-infectious hyperinflammation can be diametrically opposed.

The emergence of COVID-19 has further highlighted this diagnostic challenge, with cytokine release syndrome (CRS) and secondary HLH complicating the clinical picture². Understanding the pathophysiological underpinnings and developing practical diagnostic frameworks has become increasingly critical for improving patient outcomes in the modern ICU.

Pathophysiology: Understanding the Common Final Pathway

The Inflammatory Cascade

All hyperinflammatory conditions share a common final pathway characterized by uncontrolled macrophage activation and cytokine release³. The key mediators include:

Primary cytokines: IL-1β, TNF-α, IL-6
Secondary mediators: IL-8, IL-10, interferon-γ
Complement activation: C3a, C5a
Coagulation cascade activation

Divergent Triggers, Convergent Pathways

While the downstream inflammatory response appears similar, the initiating mechanisms differ:

Infectious triggers: Pathogen-associated molecular patterns (PAMPs) activate toll-like receptors
Autoimmune triggers: Molecular mimicry and loss of self-tolerance
Genetic triggers: Primary immunodeficiency syndromes
Drug-induced triggers: Immune checkpoint inhibitors, CAR-T therapy

Clinical Pearl: The degree of inflammatory response often exceeds what would be expected from the inciting stimulus, suggesting a dysregulated rather than appropriate immune response.

Clinical Syndromes: Definitions and Diagnostic Criteria

Hemophagocytic Lymphohistiocytosis (HLH)

HLH represents a hyperinflammatory syndrome characterized by immune system dysregulation and uncontrolled macrophage activation⁴.

HLH-2004 Diagnostic Criteria:

Molecular diagnosis OR
≥5 of the following 8 criteria:
- Fever ≥38.5°C
- Splenomegaly
- Cytopenias (≥2 cell lines)
- Hypertriglyceridemia and/or hypofibrinogenemia
- Hemophagocytosis in bone marrow, spleen, or lymph nodes
- Low/absent NK cell activity
- Ferritin ≥500 μg/L
- Elevated soluble CD25

ICU Considerations: The HLH-2004 criteria were developed for pediatric patients and may not capture adult ICU presentations optimally. The H-Score provides a more practical approach for adult patients⁵.

Macrophage Activation Syndrome (MAS)

MAS is typically associated with rheumatologic conditions, particularly systemic juvenile idiopathic arthritis⁶.

2016 Classification Criteria for MAS complicating sJIA:

Ferritin ≥684 ng/mL PLUS any 2 of:
- Platelet count ≤181 × 10⁹/L
- AST >48 U/L
- Triglycerides >156 mg/dL
- Fibrinogen ≤360 mg/dL

Severe Sepsis and Septic Shock

Sepsis-3 Definitions⁷:

Sepsis: Life-threatening organ dysfunction caused by dysregulated host response to infection
Septic Shock: Sepsis with circulatory and cellular/metabolic dysfunction

Clinical Pearl: The Sepsis-3 definition acknowledges that sepsis is fundamentally a dysregulated inflammatory response, blurring the lines with other hyperinflammatory conditions.

Cytokine Release Syndrome (CRS)

CRS encompasses acute systemic inflammatory syndromes characterized by fever and multiple organ dysfunction due to elevated cytokines⁸.

ASTCT Consensus Grading:

Grade 1: Fever with/without constitutional symptoms
Grade 2: Hypotension and/or hypoxia requiring intervention
Grade 3: Hypotension requiring high-dose vasopressors and/or hypoxia requiring high-flow oxygen
Grade 4: Life-threatening symptoms

The Diagnostic Challenge: Overlapping Features

Clinical Overlap

Common Presentations:

High-grade fever
Multi-organ dysfunction
Altered mental status
Circulatory shock
Respiratory failure

Distinguishing Features:

Feature	HLH/MAS	Severe Sepsis	CRS
Onset	Subacute (days-weeks)	Acute (hours-days)	Acute (hours-days)
Hepatosplenomegaly	Common	Less common	Variable
Lymphadenopathy	Common	Uncommon	Variable
Rash	Variable	Variable	Common
CNS involvement	Common	Variable	Less common

Laboratory Overlap

Shared Abnormalities:

Elevated inflammatory markers (CRP, PCT, ESR)
Cytopenias
Coagulopathy
Elevated LDH
Hyponatremia
Elevated liver enzymes

Discriminating Laboratory Features:

Parameter	HLH/MAS	Sepsis	Practical Threshold
Ferritin	Very high	Elevated	>1000 ng/mL suggests HLH
Fibrinogen	Low	Usually elevated	<150 mg/dL favors HLH
Triglycerides	High	Normal/low	>265 mg/dL supports HLH
LDH	Very high	Elevated	>2× ULN suggests HLH
NK cell activity	Low/absent	Normal	Requires specialized testing

Clinical Hack: The "ferritin-to-ESR ratio" >22 has been proposed as a rapid screening tool for HLH, though validation in ICU populations is limited⁹.

Advanced Diagnostic Approaches

The H-Score: A Practical Tool

The H-Score provides a probability-based approach for HLH diagnosis in adults⁵:

Parameters and Points:

Immunosuppression: 18 points
Fever: 33 points
Hepatomegaly: 23 points
Splenomegaly: 21 points
Cytopenias: 24-34 points
Ferritin level: 35-50 points
AST elevation: 19 points
Hemophagocytosis: 35 points

Interpretation:

<90 points: <1% probability
90-169 points: 1-5% probability
170-249 points: 5-85% probability
250 points: >99% probability

ICU Pearl: An H-Score >169 should prompt consideration of HLH-directed therapy, especially in the absence of convincing infectious etiology.

Cytokine Profiling

While not routinely available, cytokine profiles can provide diagnostic insights:

HLH Pattern:

Elevated IL-2R, IL-6, IL-10, IL-18
Interferon-γ pathway activation
CXCL9 elevation

Sepsis Pattern:

Early IL-1β, TNF-α elevation
Variable IL-6 and IL-10
Complement activation markers

Advanced Imaging

PET-CT Findings:

HLH: Diffuse lymphadenopathy, hepatosplenomegaly, bone marrow uptake
Sepsis: Localized infectious foci

Bone Marrow Examination

Remains the gold standard for demonstrating hemophagocytosis, though its absence doesn't exclude HLH¹⁰.

Technical Considerations:

Timing: Early in disease course
Sampling: Adequate cellularity required
Expertise: Experienced hematopathologist essential

Therapeutic Implications and Clinical Decision-Making

The Treatment Paradox

The therapeutic approaches for hyperinflammatory syndromes versus infectious causes represent opposite ends of the immunomodulatory spectrum:

Anti-inflammatory Therapy (HLH/MAS):

Corticosteroids
Cyclosporine
Etoposide
Anti-cytokine therapies (anakinra, tocilizumab)

Anti-infectious Therapy:

Broad-spectrum antibiotics
Antiviral agents
Source control
Supportive care

Clinical Dilemma: Inappropriate immunosuppression in unrecognized sepsis can be catastrophic, while delayed treatment of HLH/MAS carries equally grave consequences.

A Practical Decision Framework

Step 1: Risk Stratification

Age and comorbidities
Rapidity of onset
Severity of presentation
Response to initial management

Step 2: Infectious Workup

Comprehensive cultures
Molecular diagnostics (PCR panels)
Imaging for source identification
Biomarkers (PCT, β-D-glucan)

Step 3: Hyperinflammatory Assessment

H-Score calculation
Specialized testing (NK cell activity, sCD25)
Rheumatologic evaluation
Family history review

Step 4: Trial of Therapy

Consider empiric antimicrobials first
Early specialist consultation
Serial reassessment

Oyster Warning: Never delay antimicrobial therapy in favor of diagnostic certainty. The risk-benefit ratio favors early antibiotic treatment in most ICU scenarios.

Special Populations and Scenarios

COVID-19 and Viral-Associated HLH

The COVID-19 pandemic has highlighted the overlap between viral sepsis and secondary HLH¹¹. Key considerations:

Risk Factors for COVID-associated HLH:

Older age
Male gender
Severe lymphopenia
Markedly elevated ferritin (>2000 ng/mL)
Elevated LDH and D-dimer

Therapeutic Considerations:

Dexamethasone as standard of care
Tocilizumab for severe cases
Anakinra in selected patients

Post-Transplant Lymphoproliferative Disorder (PTLD)

PTLD represents a unique scenario where infection and hyperinflammation coexist:

EBV-driven lymphoproliferation
Secondary HLH development
Immunosuppression reduction vs. anti-HLH therapy

CAR-T Cell Therapy Complications

CAR-T therapy can trigger both infectious complications and CRS:

Grading systems (Lee criteria, ASTCT)
Tocilizumab as first-line for severe CRS
Corticosteroids for refractory cases

Monitoring and Prognostication

Serial Assessment Parameters

Daily Monitoring:

Complete blood count with differential
Comprehensive metabolic panel
Liver function tests
Coagulation studies
Inflammatory markers

Weekly Monitoring:

Ferritin trends
Triglyceride levels
LDH trends
NK cell activity (if initially abnormal)

Prognostic Indicators

Poor Prognostic Factors:

Age >60 years
CNS involvement
Multi-organ failure at presentation
Failure to respond to initial therapy
Underlying malignancy

Clinical Hack: The ferritin trend is often more informative than absolute values. Persistently rising ferritin despite appropriate therapy suggests treatment failure or incorrect diagnosis.

Emerging Therapies and Future Directions

Novel Anti-Cytokine Therapies

IL-1 Antagonists:

Anakinra: Rapid-acting, short half-life
Canakinumab: Long-acting monoclonal antibody

IL-6 Antagonists:

Tocilizumab: Proven efficacy in CRS and COVID-19
Sarilumab: Alternative IL-6 receptor antagonist

JAK Inhibitors:

Ruxolitinib: Promising in secondary HLH
Tofacitinib: Under investigation

Personalized Medicine Approaches

Genetic Testing:

Familial HLH gene panels
Pharmacogenomic considerations
Polygenic risk scores

Biomarker-Guided Therapy:

Cytokine profiling
Flow cytometry panels
Proteomic signatures

Quality Improvement and System Approaches

Multidisciplinary Teams

Core Team Members:

Intensivist
Hematologist
Rheumatologist
Infectious disease specialist
Clinical pharmacist

Institutional Protocols

Standardized Workup Algorithms:

Screening criteria implementation
Laboratory reflex testing
Consultation triggers

Treatment Pathways:

Evidence-based protocols
Safety monitoring systems
Outcome tracking

Clinical Pearls and Practical Tips

Pearls for Practice

The "Too Sick for Sepsis" Rule: When a patient appears more critically ill than would be expected from the identified infectious source, consider hyperinflammatory syndromes.
Ferritin Kinetics: In true HLH, ferritin often exceeds 10,000 ng/mL and continues rising despite treatment. In sepsis, ferritin typically plateaus below 5,000 ng/mL.
The Platelet Paradox: Severe thrombocytopenia with concurrent bleeding and thrombosis should raise suspicion for HLH rather than typical sepsis.
Family History Red Flags: Any family history of unexplained childhood deaths, recurrent infections, or autoimmune diseases should prompt consideration of primary HLH.
Response to Steroids: Rapid improvement with corticosteroids may suggest hyperinflammatory conditions, though this is not pathognomonic.

Oysters (Common Pitfalls)

The Infection Bias: ICU physicians are trained to "think horses, not zebras," but hyperinflammatory syndromes are increasingly common in modern ICUs.
Culture-Negative Sepsis: Not all culture-negative "sepsis" is infectious. Consider HLH/MAS when cultures remain negative despite appropriate sampling.
Steroid Responsiveness: Improvement with steroids doesn't exclude infection; some infectious processes (PCP pneumonia, TB) also respond to corticosteroids.
The Timing Trap: HLH can be triggered by infection, creating a scenario where both conditions coexist temporally.
Laboratory Limitations: Normal ferritin doesn't exclude HLH, and elevated ferritin doesn't confirm it. Context is crucial.

Clinical Hacks

The "Ferritin Velocity" Concept: Calculate ferritin rise per day. Values >1,000 ng/mL/day suggest hyperinflammation over infection.
The "Spleen Sign": In hemodynamically stable patients, bedside ultrasound assessment of spleen size can provide rapid diagnostic information.
The "Fibrinogen Flip": Serial fibrinogen measurements can help differentiate early sepsis (rising) from HLH (falling).
The "Temperature-Tachycardia Dissociation": Relative bradycardia despite high fever may suggest HLH over bacterial sepsis.
The "Cytokine Window": If cytokine testing is available, samples should be obtained within 24-48 hours of presentation for optimal diagnostic yield.

Future Research Directions

Diagnostic Innovation

Point-of-Care Testing:

Rapid cytokine assays
Portable flow cytometry
AI-assisted pattern recognition

Omics Approaches:

Transcriptomic signatures
Metabolomic profiling
Microbiome analysis

Therapeutic Advances

Precision Medicine:

Biomarker-guided therapy selection
Pharmacogenomic optimization
Real-time treatment monitoring

Novel Targets:

Complement inhibition
Neutrophil extracellular trap modulation
Mitochondrial dysfunction correction

Conclusion

The differentiation between hyperinflammatory syndromes and infectious processes in the ICU represents one of the most challenging aspects of critical care medicine. While these conditions share significant phenotypic overlap, understanding their pathophysiological differences and applying systematic diagnostic approaches can improve patient outcomes.

Key takeaways for the practicing intensivist include:

Maintain high clinical suspicion for hyperinflammatory syndromes in patients with severe systemic inflammation disproportionate to identified infectious sources
Utilize validated scoring systems like the H-Score to guide diagnostic probability
Implement multidisciplinary approaches early in the diagnostic process
Consider empiric antimicrobial therapy while pursuing hyperinflammatory workup
Monitor treatment response closely and maintain diagnostic flexibility

As our understanding of these complex syndromes evolves, the integration of advanced diagnostics, personalized medicine approaches, and novel therapeutic targets will likely improve our ability to navigate this diagnostic grey zone. Until then, clinical vigilance, systematic assessment, and multidisciplinary collaboration remain our most powerful tools.

The ultimate goal remains the same: rapid recognition and appropriate treatment of critically ill patients, whether their condition stems from infection, hyperinflammation, or the complex interplay between both processes.

References

Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-1516.
McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6):102537.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620.
Ravelli A, Minoia F, Davì S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation collaborative initiative. Ann Rheum Dis. 2016;75(3):481-489.
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.
Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625-638.
Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72(2):326-334.
Retamozo S, Brito-Zerón P, Sisó-Almirall A, et al. Haemophagocytic syndrome and COVID-19. Clin Rheumatol. 2021;40(4):1233-1244.
Prilutskiy A, Kritselis M, Shevtsov A, et al. SARS-CoV-2 infection-associated hemophagocytic lymphohistiocytosis: an autopsy series with clinical and laboratory correlation. Am J Clin Pathol. 2021;155(4):466-474.

Author Information

Conflicts of Interest: The authors declare no conflicts of interest.

Funding: No specific funding was received for this work.

Word Count: 3,847 words

Monday, August 25, 2025